← Leaderboards
Viktor Adalsteinsson
Broad Institute, Inc.
$814,958
Attributed
$1,990,684
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $657.6K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,990,684 · 3
By mechanism
R01$908,380 · 1
UH3$761,769 · 1
UH2$320,535 · 1
Top collaborators
- Niall John Lennon5 shared
- Daniel G. Stover5 shared
- G. Mike Makrigiorgos2 shared
Most similar at Broad Institute, Inc.
Same institution · by research overlap
- Catherine Ju-Ying Wu$43,266,044
- Andrew David Cherniack$2,099,714
- Daniel G. Stover$777,584
- Katherine Jane Megquier$330,781
- Fei Chen$12,921,245
Others in their field
Other Emerging Leaders on “Tumor Dna”
- Leonard Freedman · Leidos Biomedical Research, Inc.$56,902,083
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$32,178,580
- Lynn Briscoe · Leidos Biomedical Research, Inc.$25,343,101
- Olwen Hahn · Brigham And Women'S Hospital$23,582,395
- Elizabeth Fox · St. Jude Children'S Research Hospital$8,840,232
- J. Silvio Gutkind · University Of California, San Diego$7,798,981
Research focus
Tumor DnaInnovationSamplingBloodMalignant NeoplasmsCollectionLiquid BiopsyMutationWhole GenomeDetectionTumorCancer TypeGenome SequencingBreastBlood TestsBlood SpecimenEstrogen Receptor PositiveGenomic BiomarkerIneffective TherapiesCell Free DnaCell FractionBiopsyAssay DevelopmentAdvanced Malignant Neoplasm
Grant awards (7)
Comprehensive minimal residual disease tracking in cancer$444,440
R01 · FY2025 · CA
Comprehensive minimal residual disease tracking in cancer$463,940
R01 · FY2024 · CA
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$193,674
UH3 · FY2024 · CA
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$274,067
UH3 · FY2023 · CA
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$294,028
UH3 · FY2022 · CA
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$105,636
UH2 · FY2021 · CA
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers$214,899
UH2 · FY2020 · CA